U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
IRVINE, Calif., April 24, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq:SCYX). Investors who purchased shares (1) pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company’s Initial Public Offering on or about May 2, 2014 and/or (2) between May 2, 2014 and March 2, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 8, 2017 lead plaintiff motion deadline.
If you purchased SCYNEXIS shares during the IPO or Class Period, please contact Joon M. Khang, Esq., of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, SCYNEXIS made false and/or misleading statements and/or failed to disclose: that the Company’s lead product, SCY-078, posed substantial undisclosed health and safety risks; that SCYNEXIS overstated the drug’s approval prospects and/or commercial viability; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On March 2, 2017, SCYNEXIS announced that the U.S. Food and Drug Administration “informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data” of the formulation. The hold stems from “three mild-to-moderate thrombotic events in healthy volunteers” receiving the formulation. When this news was announced, the stock price of SCYNEXIS fell significantly, thus harming investors.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
